Ginsenoside Rg4
Based on 1 Customer Validation
Ginsenoside Rg4 is an orally active protopanaxatriol type ginsenoside. Ginsenoside Rg4 can activate PI3K, AKT and GSK-3β signaling. Ginsenoside Rg4 can inhibit ROS and inflammatory cytokine levels. Ginsenoside Rg4 can be used for the researches of inflammation, infection and metabolic disease, such as sepsis and lung inflammation.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.94%
- CAS. Nr.: 126223-28-7
- Formel: C42H70O12
- Molecular Weight:767.00
-
Speicherung:
-80°C, protect from light
Alle TNF Receptor Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
GSK-3β |
IL-1β |
TNF-α |
In Vitro
Ginsenoside Rg4 (0.01-0.2 mg/mL, 6 h) decreases the expressions of toll-like receptor (TLR) 4 and TNF-α levels in HMGB1-activated HUVECs[1].
Ginsenoside Rg4 (0.1-0.2 mg/mL, 6 h) increases cell viability by activating PI3K/AKT signaling in HMGB1-activated HUVECs[1].
Ginsenoside Rg4 (20-50 μg/mL, 48 h) promotes the hair-inductive properties of DP cells by activating the AKT/GSK3β/β-catenin signaling pathway in dermal papilla (DP) sphere[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HMGB1-activated HUVECs
-
Concentration:0.01, 0. 1 and 0.2 mg/mL
-
Incubation Time:6 h
-
Result:Reduced TLR2, TLR4 and NF-κB expression.
In Vivo
Ginsenoside Rg4 (1-15 mg/kg, p.o., for 10 days) attenuates inflammation in PM2.5-induced pulmonary inflammation mice models[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cecal ligation and puncture (CLP)-induced sepsis mice models[1]
-
Dosage:10 and 15 mg/kg
-
Administration:Intravenously injection, 24 h after CLP
-
Result:Reduced TNF-α and IL-1β levels.
Reduced nitric oxide (NO) levels and renal inflammation.
Increased PI3k and p-AKT levels.
-
Animal Model:PM2.5-induced pulmonary inflammation mice models[3]
-
Dosage:1, 2, 4, 7.5 and 15 mg/kg
-
Administration:Orally administration, for 10 days
-
Result:Reduced ROS levels.
Inhibited activation of p38 mitogen-activated protein kinase (MAPK) .
Activated Akt in purified pulmonary endothelial cells.
Reduced vascular protein leakage and leukocyte infiltration.
Reduced proinflammatory cytokine release in bronchoalveolar lavage fluids.
Chemical Information
-
CAS. Nr. 126223-28-7
-
Appearance Solid
-
Molecular Weight 767.00
-
Formel C42H70O12
-
Color White to off-white
-
SMILES
C[C@]12[C@@]3(C)[C@@]([H])([C@H](CC3)/C(C)=C\C/C=C(C)\C)[C@@H](C[C@@]1([C@]4(C)[C@@]([H])([C@H](C2)O[C@]5([C@H](O[C@]6([C@H](O)[C@H](O)[C@H]([C@@H](O6)C)O)[H])[C@@H](O)[C@@H]([C@H](O5)CO)O)[H])C([C@H](CC4)O)(C)C)[H])O
-
Structure Classification
-
Initial Source
-
Versand
Shipping with dry ice.
-
Speicherung
-80°C, protect from light
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 5 mg/mL (6.52 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months (protect from light). When stored at -80°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months (protect from light). When stored at -80°C, please use it within 6 months.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Protokoll
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Reinheit & Dokumentation
-
Data Sheet (284 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Kim GO, et al. Inhibitory Activities of Rare Ginsenoside Rg4 on Cecal Ligation and Puncture-Induced Sepsis. Int J Mol Sci. 2022 Sep 16;23(18):10836. [Content Brief]
[2]. Lee YH, et al. Ginsenoside Rg4 Enhances the Inductive Effects of Human Dermal Papilla Spheres on Hair Growth Via the AKT/GSK-3β/β-Catenin Signaling Pathway. J Microbiol Biotechnol. 2021 Jul 28;31(7):933-941. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months (protect from light). When stored at -80°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.3038 mL | 6.5189 mL | 13.0378 mL | 32.5945 mL |
| 5 mM | 0.2608 mL | 1.3038 mL | 2.6076 mL | 6.5189 mL |